Protalix: Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

CARMIEL, Israel - Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today announced that its management will be participating in the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025, to be held virtually March 25-26, 2025 . iAccess Alpha hosts virtual investor conferences featuring companies recommended by investors. These two-day events include webcast presentations on Day 1, followed by one-on-one meetings between Protalix management and pre-qualified investors on Day 2. For more information about the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025, or to register and schedule a one-on-one meeting with Protalix , please visit the conference website at: https://www.iaccessalpha.com/home . iAccess Alpha Virtual Best Ideas Spring Conference 2025 Live Presentation Date: Tuesday, March 25, 2025 Time: 12:00 p.m. Eastern Daylight Time (EDT) Company Link: https://ir.protalix.com/news-events/events Webcast Link: https://tinyurl.com/yekbs6k6 Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for at least six months on the Events Calendar of the Investors section of Protalix's website, at the above link. About Protalix BioTherapeutics, Inc. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil , where Protalix retains full rights. Protalix's second product, Elfabrio, was approved by both the FDA and the European Medicines Agency in May 2023 . Protalix has partnered with Chiesi Farmaceutici S.p.A . for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX-119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others. Contact: Investor Mike Moyer Managing Director LifeSci Advisors +1-617-308-4306 mmoyer@lifesciadvisors.com (C) 2025 Electronic News Publishing, source ENP Newswire CARMIEL, Israel - Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today announced that its management will be participating in the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025, to be held virtually March 25-26, 2025 . iAccess Alpha hosts virtual investor conferences featuring companies recommended by investors. These two-day events include webcast presentations on Day 1, followed by one-on-one meetings between Protalix management and pre-qualified investors on Day 2. For more information about the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025, or to register and schedule a one-on-one meeting with Protalix , please visit the conference website at: https://www.iaccessalpha.com/home . iAccess Alpha Virtual Best Ideas Spring Conference 2025 Live Presentation Date: Tuesday, March 25, 2025 Time: 12:00 p.m. Eastern Daylight Time (EDT) Company Link: https://ir.protalix.com/news-events/events Webcast Link: https://tinyurl.com/yekbs6k6 Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for at least six months on the Events Calendar of the Investors section of Protalix's website, at the above link. About Protalix BioTherapeutics, Inc. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil , where Protalix retains full rights. Protalix's second product, Elfabrio, was approved by both the FDA and the European Medicines Agency in May 2023 . Protalix has partnered with Chiesi Farmaceutici S.p.A . for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX-119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others. Contact: Investor Mike Moyer Managing Director LifeSci Advisors +1-617-308-4306 mmoyer@lifesciadvisors.com (C) 2025 Electronic News Publishing, source ENP Newswire